[
  {
    "ts": "2026-02-24T07:11:08+00:00",
    "headline": "FDA Approves AbbVie (ABBV) VENCLEXTA and Acalabrutinib Combination for First-Line CLL",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best value stocks to buy now. On February 20, the US FDA approved the combination of VENCLEXTA (venetoclax) and acalabrutinib as a first-line treatment for adults with chronic lymphocytic leukemia/CLL. This establishes the first and only all-oral, fixed-duration regimen for previously untreated patients, providing a new alternative to […]",
    "url": "https://finance.yahoo.com/news/fda-approves-abbvie-abbv-venclexta-071108164.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "893775cf-1617-39f1-b268-520fb5ad30b4",
      "content": {
        "id": "893775cf-1617-39f1-b268-520fb5ad30b4",
        "contentType": "STORY",
        "title": "FDA Approves AbbVie (ABBV) VENCLEXTA and Acalabrutinib Combination for First-Line CLL",
        "description": "",
        "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best value stocks to buy now. On February 20, the US FDA approved the combination of VENCLEXTA (venetoclax) and acalabrutinib as a first-line treatment for adults with chronic lymphocytic leukemia/CLL. This establishes the first and only all-oral, fixed-duration regimen for previously untreated patients, providing a new alternative to […]",
        "pubDate": "2026-02-24T07:11:08Z",
        "displayTime": "2026-02-24T07:11:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/1e9120b21df9d4584216be519950b41a",
          "originalWidth": 1280,
          "originalHeight": 853,
          "caption": "FDA Approves AbbVie (ABBV) VENCLEXTA and Acalabrutinib Combination for First-Line CLL",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fMTKP7t.2d.zV8tkJ89T9A--~B/aD04NTM7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/1e9120b21df9d4584216be519950b41a.cf.webp",
              "width": 1280,
              "height": 853,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/02t2dAWp2fmON9uUD0DVog--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/1e9120b21df9d4584216be519950b41a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fda-approves-abbvie-abbv-venclexta-071108164.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-approves-abbvie-abbv-venclexta-071108164.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]